BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33269269)

  • 1. Successful treatment of relapsed acute promyelocytic leukemia with arsenic trioxide in a hemodialysis-dependent patient: A case report.
    Lee HJ; Park SG
    World J Clin Cases; 2020 Nov; 8(21):5347-5352. PubMed ID: 33269269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [All-trans retinoic acid/arsenic trioxide combination therapy for a patient with acute promyelocytic leukemia on dialysis].
    Nagao R; Hosoba R; Yahagi Y; Gunji T; Uryu H; Hattori D; Momoki M; Yamazaki H
    Rinsho Ketsueki; 2019; 60(10):1431-1435. PubMed ID: 31695003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term remission after first-line single-agent treatment with arsenic trioxide of relapsed acute promyelocytic leukemia in an 8-year-old boy.
    Ebinger M; Schwarze CP; Feuchtinger T; Scheel-Walter HG; Lang P; Hildenbrand S; Gessler P; Handgretinger R
    Pediatr Hematol Oncol; 2011 May; 28(4):334-7. PubMed ID: 21345080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.
    Soignet SL; Frankel SR; Douer D; Tallman MS; Kantarjian H; Calleja E; Stone RM; Kalaycio M; Scheinberg DA; Steinherz P; Sievers EL; Coutré S; Dahlberg S; Ellison R; Warrell RP
    J Clin Oncol; 2001 Sep; 19(18):3852-60. PubMed ID: 11559723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
    Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia.
    Zhang T; Ma D; Wei D; Lu T; Yu K; Zhang Z; Wang W; Fang Q; Wang J
    Anticancer Drugs; 2020 Feb; 31(2):158-168. PubMed ID: 31584454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
    Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
    Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child.
    Rock N; Mattiello V; Judas C; Huezo-Diaz P; Bourquin JP; Gumy-Pause F; Ansari M
    Pediatr Hematol Oncol; 2014 Mar; 31(2):143-8. PubMed ID: 24498972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
    Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
    BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
    Xu SN; Chen JP; Liu JP; Xia Y
    Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
    Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
    Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arsenic trioxide for acute promyelocytic leukemia in a patient on chronic hemodialysis.
    Tinajero J; El-Shami K; Wu X; Smith BD; Newman MJ
    Leuk Res Rep; 2022; 17():100304. PubMed ID: 35371914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world data on the dose-related effect of arsenic trioxide in the relapse of acute promyelocytic leukemia.
    Gong S; Wang H; Zhang H; Liu W; Zhang X; Zhao C
    Mol Clin Oncol; 2020 Dec; 13(6):91. PubMed ID: 33194197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Acute promyelocytic leukemia: state-of-the-art management].
    Asou N
    Rinsho Ketsueki; 2018; 59(6):725-734. PubMed ID: 29973452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
    Cicconi L; Breccia M; Franceschini L; Latagliata R; Molica M; Divona M; Diverio D; Rizzo M; Ottone T; Iaccarino L; Alfonso V; Foa R; Voso MT; Lo-Coco F
    Ann Hematol; 2018 Oct; 97(10):1797-1802. PubMed ID: 29951912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada.
    Lachaine J; Mathurin K; Barakat S; Couban S
    Eur J Haematol; 2015 Sep; 95(3):218-29. PubMed ID: 25354894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Case of Relapsed/Refractory CD56-Positive Acute Promyelocytic Leukemia, in Which Complete Molecular Remission Was Achieved Following Combination Therapy with Venetoclax and Azacitidine.
    Sekiguchi Y; Tsutsumi H; Gomyo A; Kudo M; Maseki N; Iizaki Y; Kawamura M; Kobayashi K; Nitta H; Noguchi M; Wakita S; Yamaguchi H; Kobayashi H
    Gan To Kagaku Ryoho; 2024 Mar; 51(3):291-297. PubMed ID: 38494811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
    Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
    Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure.
    Firkin F; Roncolato F; Ho WK
    Eur J Haematol; 2015 Oct; 95(4):331-5. PubMed ID: 25600167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy.
    Ghavamzadeh A; Alimoghaddam K; Ghaffari SH; Rostami S; Jahani M; Hosseini R; Mossavi A; Baybordi E; Khodabadeh A; Iravani M; Bahar B; Mortazavi Y; Totonchi M; Aghdami N
    Ann Oncol; 2006 Jan; 17(1):131-4. PubMed ID: 16227315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.